Analyst Ratings For Achieve Life Sciences Inc (NASDAQ:ACHV)
Today, LADENBURG THALM/SH SH reiterated its Buy rating on Achieve Life Sciences Inc (NASDAQ:ACHV) with a price target of $20.00.
There are 2 Buy Ratings, no Strong Buy Ratings, no Sell Ratings, no Hold Ratings on the stock.
The current consensus rating on Achieve Life Sciences Inc (NASDAQ:ACHV) is Buy with a consensus target price of $13.00 per share, a potential 625.53% upside.
Some recent analyst ratings include
- 8/9/2019-Achieve Life Sciences Inc (NASDAQ:ACHV) had its Buy rating reiterated by LADENBURG THALM/SH SH with a $20.00 price target
- 7/24/2019-Achieve Life Sciences Inc (NASDAQ:ACHV) had its Buy rating reiterated by Maxim Group with a $6.00 price target
- On 6/11/2019 Armistice Capital Master Fund, Major Shareholder, bought 12,813 with an average share price of $3.80 per share and the total transaction amounting to $48,689.40.
- On 5/23/2019 Richard Alistair Stewart, CEO, bought 17,500 with an average share price of $3.61 per share and the total transaction amounting to $63,175.00.
- On 8/19/2016 John Bencich, CFO, sold 1,380 with an average share price of $0.57 per share and the total transaction amounting to $786.60.
- On 6/13/2016 Cindy Jacobs, CMO, sold 1,437 with an average share price of $1.03 per share and the total transaction amounting to $1,480.11.
- On 6/13/2016 Scott Daniel Cormack, CEO, sold 4,856 with an average share price of $1.03 per share and the total transaction amounting to $5,001.68.
- On 3/15/2016 Cindy Jacobs, CMO, sold 3,254 with an average share price of $0.83 per share and the total transaction amounting to $2,700.82.
- On 3/15/2016 John Bencich, CFO, sold 834 with an average share price of $0.83 per share and the total transaction amounting to $692.22.
About Achieve Life Sciences Inc (NASDAQ:ACHV)
Achieve Life Sciences, Inc, a clinical-stage pharmaceutical company, develops and commercializes smoking cessation aids in the United States and internationally. The company offers Cytisine, a plant-based alkaloid that interacts with nicotine receptors in the brain to help reduce the severity of nicotine withdrawal symptoms. It has a license agreement with Sopharma AD and University of Bristol. Read More…
Recent Trading Activity for Achieve Life Sciences Inc (NASDAQ:ACHV)
Shares of Achieve Life Sciences Inc closed the previous trading session at 1.79 −0.058 3.15% with 1.7 shares trading hands.